News >

FDA Grants Abatacept Breakthrough Designation for Acute GVHD

Gina Columbus @ginacolumbusonc
Published: Wednesday, Dec 04, 2019

Leslie Kean, MD, director of the Stem Cell Transplantation Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Leslie Kean, MD

The FDA has granted a breakthrough therapy designation for abatacept (Orencia) for the prevention of moderate-to-severe acute graft-versus-host disease (GVHD) in patients who have undergone hematopoietic stem cell transplants (HSCTs) from unrelated donors.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication